Endocrine Consequences of Long-Term Intrathecal Administration of Opioids
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Intrathecal administration of opioids is a very efficient tool in the long-term control of intractable nonmalignant pain. However, despite the well known role of opioids in endocrine regulation, few data are available about possible effects on hypothalamic-pituitary function during this treatment. Seventy-three patients (29 men and 44 women; mean age, 49.2 ± 11.7 yr) receiving opioids intrathecally for nonmalignant pain were enrolled for extensive endocrine investigation. At the time of hormonal determination, the mean duration of opioid treatment was 26.6 ± 16.3 months; the mean daily dose of morphine was 4.8 ± 3.2 mg. The control group consisted of 20 patients (11 men and 9 women; mean age, 54.2 ± 14.0 yr) with a comparable pain syndrome but not treated with opioids. Decreased libido or impotency was present in 23 of 24 men receiving opioids. The serum testosterone level was below 9 nmol/L in 25 of 29 men and was significantly lower than that in the control group (P < 0.001). The free androgen index was below normal in 18 of 29 men and was significantly lower than that in the control group (P < 0.001). The serum LH level was less than 2 U/L in 20 of 29 men and was significantly lower than that in the control group (P < 0.001). Serum FSH was comparable in both groups. Decreased libido was present in 22 of 32 women receiving opioids. All 21 premenopausal females developed either amenorrhea or an irregular menstrual cycle, with ovulation in only 1. Serum LH, estradiol, and progesterone levels were lower in the opioid group. In all 18 postmenopausal females significantly decreased serum LH (P < 0.001) and FSH (P = 0.012) levels were found. The 24-h urinary free cortisol excretion was below 20 μg/day in 14 of 71 opioid patients and was significantly lower than that in the control group (P = 0.003). The peak cortisol response to insulin-induced hypoglycemia was below 180 μg/L in 9 of 61 opioid patients and was significantly lower than that in the nonopioid group (P = 0.002). The insulin-like growth factor I sd score was below −2 sd in 12 of 73 opioid patients and was significantly lower than that in the control group (P = 0.002). The peak GH response to hypoglycemia was below 3 μg/L in 9 of 62 subjects and was significantly lower than that in the control group (P = 0.010). Thyroid function tests and PRL levels were considered normal. No metabolic disturbances were recorded, apart from significantly decreased high density lipoprotein cholesterol levels (P = 0.041) and elevated total/high density lipoprotein cholesterol ratio (P = 0.008) in the opioid group compared to the control group. Supplementation with gonadal steroids improved sexual function in most patients. In conclusion, of all patients receiving intrathecal opioids, the large majority of men and all women developed hypogonadotropic hypogonadism, about 15% developed central hypocorticism, and about 15% developed GH deficiency. These findings suggest that further investigations are required to determine the need for systematic endocrine work-up in these patients and the necessity for substitutive therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A landmark study published 3 years later, investigating the effects of intrathecal opioids using the insulin tolerance test (ITT) (the gold standard for the diagnosis of secondary adrenal insufficiency), showed that 15% (9/61) of the patients on intrathecal opioids for nonmalignant pain had secondary adrenal insufficiency (74).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [74]
In the citing paper
“These results suggest that up to 17% of the patients treated with intrathecal opioids may develop GH deficiency (74).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [74]
In the citing paper
“Twelve opioid-treated patients (17%) had an IGF-I SD score below -2 SD, as opposed to no such case in the control group.”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [74]
In the citing paper
“Nine opioid-treated patients (15%) had a peak GH value consistent with severe GH deficiency (below 3 mcg/L), a finding not demonstrated in any control patient.”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [74]
In the citing paper
“The opioid-treated group had lower mean serum IGF-I (138.5 mcg/L ± 64.1) in comparison to the controls (162.0mcg/L ± 55.3; P = .045),as well as lower IGF-I SD score (-0.53 ± 1.45 and 0.57 ± 1.00; P = .002).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [74]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A quantitative approach to perceived health status: a validation study
Hunt, S. M., McKenna, S. P., McEwen, J., Backett, E. M., Williams, J., & Papp, E. (1980) · Journal of Epidemiology and Community Health · doi:10.1136/jech.34.4.281 · Cited by 924
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822
Side effects of intrathecal and epidural opioids
Chaney, M. A. (1995) · Canadian Journal of Anaesthesia · doi:10.1007/bf03011037 · Cited by 562
The Diagnosis of Growth Hormone Deficiency in Adults
Ho, K. K. Y., & Hoffman, D. M. (1997) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.6.suppl10_35 · Cited by 428
Diagnosis of growth-hormone deficiency in adults
Hoffman, D. M., O'Sullivan, A. J., Ho, K. K. Y., & Baxter, R. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90181-3 · Cited by 386
The growth hormone deficiency syndrome in adults
Cuneo, R. C., Salomon, F., McGauley, G. A., & Sönksen, P. H. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02347.x · Cited by 375
Winkelmüller, M., & Winkelmüller, W. (1996) · Journal of Neurosurgery · doi:10.3171/jns.1996.85.3.0458 · Cited by 333
Intraspinal morphine for chronic pain: A retrospective, multicenter study
Paice, J. A., Penn, R. D., & Shott, S. (1996) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(95)00099-2 · Cited by 302
The endocrinology of the opiates and opioid peptides
Morley, J. E. (1981) · Metabolism · doi:10.1016/0026-0495(81)90172-4 · Cited by 283
The Use of Opioids for the Treatment of Chronic Pain*
&NA; (1997) · The Clinical Journal of Pain · doi:10.1097/00002508-199703000-00003 · Cited by 208
Differential Effects of Opiate Peptides and Alkaloids on Anterior Pituitary Hormone Secretion
Delitala, G., Grossman, A., & Besser, M. (1983) · Neuroendocrinology · doi:10.1159/000123558 · Cited by 184
Intraspinal opioid therapy for chronic nonmalignant pain: Current practice and clinical guidelines
Krames, E. S. (1996) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(96)00010-3 · Cited by 183
Gonadal function in male heroin and methadone addicts
RAGNI, G., de LAURETIS, L., BESTETTI, O., SGHEDONI, D., & ARO, V. G. A. (1988) · International Journal of Andrology · doi:10.1111/j.1365-2605.1988.tb00984.x · Cited by 169
Adverse Effects of Systemic Opioid Analgesics
Schug, S. A., Zech, D., & Grond, S. (1992) · Drug Safety · doi:10.2165/00002018-199207030-00005 · Cited by 167
Altered sexual function and decreased testosterone in patients receiving intraspinal opioids
Pake, J. A., Penn, R. D., & Ryan, W. G. (1994) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(94)90166-x · Cited by 140
Decreased serum testosterone concentration in male heroin and methadone addicts
Azizi, F., Vagenakis, A. G., Longcope, C., Ingbar, S. H., & Braverman, L. E. (1973) · Steroids · doi:10.1016/0039-128x(73)90002-0 · Cited by 130
RASMUSSEN, D. D., LIU, J. H., WOLF, P. L., & YEN, S. S. C. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-5-881 · Cited by 122
Gybels, J., Erdine, S., Maeyaert, J., Meyerson, B. A., Winkelmüller, W., Augustinsson, L.-E., Bonezzi, C., Brasseur, L., Dejongste, M. J. L., Kupers, R. C., et al. (1998) · European Journal of Pain · doi:10.1016/s1090-3801(98)90016-7 · Cited by 113
Self-citationBrain opiates and neuroendocrine function
Grossman, A. B. (1983) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(83)80062-0 · Cited by 104
Clinical realities and economic considerations: Economics of intrathecal therapy
Hassenbusch, S. J., Paice, J. A., Patt, R. B., Bedder, M. D., & Bell, G. K. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(97)00169-3 · Cited by 103
A comparison of the adrenal responses to hypoglycemia, metyrapone and ACTH
Nelson, J. C., & TINDALL, D. J. (1978) · The American Journal of the Medical Sciences · doi:10.1097/00000441-197803000-00006 · Cited by 86
Different Opioid Mechanisms Are Involved in the Modulation of ACTH and Gonadotrophin Release in Man
Grossman, A. B., MOULT, P. J. A., Cunnah, D., & Besser, M. (2008) · Neuroendocrinology · doi:10.1159/000124463 · Cited by 73
Hypothalamus-pituitary-adrenal axis of heroin addicts
Facchinetti, F., Volpe, A., Farci, G., Petraglia, F., Porro, C. A., Barbieri, G., Cioni, A., Balestrieri, A., & Genazzani, A. R. (1985) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(85)90014-6 · Cited by 61
Supression of plasma cortisol in depressed patients by acute intravenous methadone infusion
Gold, P. W., Extein, I., Pickar, D., Rebar, R., Ross, R., & Goodwin, F. K. (1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.7.862 · Cited by 60
Clinical realities and economic considerations: Efficacy of intrathecal pain therapy
Paice, J. A., Winkelmüller, W., Burchiel, K. J., Racz, G. B., & Prager, J. P. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(97)00167-x · Cited by 59
Portenoy, R. K., & Savage, S. R. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(97)00168-1 · Cited by 52
Role of Epidural and Intrathecal Narcotics and Peptides in the Management of Cancer Pain
Payne, R. (1987) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30873-2 · Cited by 50
Methadone induced hypoadrenalism
Dackis, C. A., Gurpegui, M., Pottash, A. L. C., & Gold, M. S. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92830-6 · Cited by 49
Wulf, H., Gleim, M., & Mignat, C. (1994) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(94)90189-9 · Cited by 48
Psychoneuroendocrine effects of methadone maintenance
Willenbring, M. L., Morley, J. E., Krahn, D. D., Carlson, G. A., Levine, A. S., & Shafer, R. B. (1989) · Psychoneuroendocrinology · doi:10.1016/0306-4530(89)90007-3 · Cited by 47
Su, C., Liu, M. Y., & Lin, M. T. (1987) · Journal of Neurology · doi:10.1007/bf00718020 · Cited by 36
Heroin addiction and sex hormones in males.
Malik, S. A., Khan, C., Jabbar, A., & Iqbal, A. (1992) · PubMed · Cited by 27
MURAKAWA, T., Nagao, H., Baba, S., Kudo, T., MATSUKI, A., Oyama, T., Ishigooka, T., Machida, S., Sato, K., & Sato, M. (1989) · PubMed · Cited by 2
Research works printed but not linked: 1
- Gijbels, 1998, Neuromodulation of pain. A consensus statement of the European Federation of IASP Chapters (EFIC)., Eur J Pain, 2, 203
Cited by
Opioid Complications and Side Effects
Benyamin, R. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/s105 · Cited by 2,245
Opioids in chronic non-cancer pain: systematic review of efficacy and safety
Kalso, E., Edwards, J. E., Moore, A. R., & McQuay, H. J. (2004) · Pain · doi:10.1016/j.pain.2004.09.019 · Cited by 1,216
Opioid Therapy for Chronic Pain
Ballantyne, J. C., & Mao, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra025411 · Cited by 959
(2005) · doi:10.1016/j.ucl.2005.08.007 · Cited by 759
Long-term opioid management for chronic noncancer pain
Noble, M., Treadwell, J. R., Tregear, S. J., Coates, V. H., Wiffen, P. J., Akafomo, C., Schoelles, K. M., & Chou, R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006605.pub2 · Cited by 735
Metadata
- Authors
- Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J.-P., Opsomer, F., Adriaensen, H., Verlooy, J., Van Havenbergh, T., Smet, M., & Van Acker, K.
- Affiliations
- Antwerp University Hospital (BE)
- Maria Middelares Hospital St. Niklaas (J.-P.V.B.), B-2650 Edegem, Belgium
- ZNA Middelheim Hospital (BE)
- Department of Neurosurgery, University Hospital Antwerp (J.V., T.V.H.), B-2650 Edegem, Belgium
- Department of Endocrinology, University Hospital Antwerp (R.A., K.V.A.), B-2650 Edegem, Belgium
- ORCID
- Smet, Mike
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-06-01
- Volume
- 85
- Issue
- 6
- Pages
- 2215-2222
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2135470636
- Cited by
- 491
- References
- 33
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 16 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 17 · 2019: 23 · 2018: 23 · 2017: 20 · 2016: 21 · 2015: 21 · 2014: 20 · 2013: 26 · 2012: 32
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- intrathecal opioids, morphine, hypothalamic-pituitary function, testosterone, free androgen index, luteinizing hormone, follicle-stimulating hormone, amenorrhea, menstrual cycle, sexual desire, erectile dysfunction, urinary free cortisol, insulin-induced hypoglycemia, cortisol response, hypothalamic-pituitary-adrenal axis, chronic non-cancer pain
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amenorrhea, Analgesics, Opioid, Androgens, Blood Pressure, Hydromorphone, Estradiol, Female, Follicle Stimulating Hormone, Hormones, Humans, Hydrocortisone, Erectile Dysfunction, Injections, Spinal, Luteinizing Hormone, Libido, Male, Middle Aged, Morphine, Pain, Intractable, Intractable Pain, Progesterone, Reference Values, Retrospective Studies, Sex Hormone-Binding Globulin, Premenopause, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.